Symetis' transfemoral heart valve wins EU approval | Report: Ablation tech market could hit $2.41B by 2019 | Stock sale could bring in $26.6M for Corindus
Web Version
September 15, 2014
ADVAMED SmartBrief
News for medical technology professionals

Top StorySponsored By
Symetis' transfemoral heart valve wins EU approval
Symetis has received the CE mark in Europe for its Acurate neo system, a transcatheter aortic valve implant delivered via a transfemoral approach. The Swiss device firm joins Medtronic and Edwards Lifesciences as the only companies that offer TAVI devices with both transfemoral and transapical delivery options. (Boston) (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
Thinking of Outsourcing Sales? Think Fast.
The Success of your Medical or Diagnostic Product depends on it.
The decision to outsource sales indicates the need is current and imperative to implement rapidly. This requires the right partner with a customized approach that allows you to meet market potential. Proven Sales Team Design, Onboarding, Real-time Metrics and Reporting—Learn more.
Business & Market Trends
Report: Ablation tech market could hit $2.41B by 2019
A MarketsandMarkets report predicts that the worldwide market for ablation devices could rise to about $2.41 billion in five years, driven in part by technological developments. The market is dominated by North America, but the biggest annual growth from 2014 to 2019 is likely to come from the Asia-Pacific region, the report says. (free registration) (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
Stock sale could bring in $26.6M for Corindus
Corindus Vascular Robotics, which has operations in the U.S. and Israel, expects to obtain $26.6 million in a private shares offering. The company, which specializes in precision vascular robotic tools for catheterization and remote heart procedures, will use part of the proceeds to expand its sales force, CEO David Handler said. Globes (Israel) (9/14)
Share: LinkedInTwitterFacebookGoogle+Email
Medigus reports MUSE device trial results, wins funds
Medigus has announced that its MUSE, or Medigus Ultrasonic Surgical Endostapler, system demonstrated promising results in a clinical study evaluating the use of the device in patients with gastroesophageal reflux disease. The Israel-based company also has secured $5.6 million in a round of financing from five investors. (Boston) (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
International Developments
World's greenest companies include Abbott, Medtronic
Abbott has been recognized by the Dow Jones Sustainability World Index as among the companies with the most environmentally friendly practices, emerging as the leader in the health care segment. Also making the list is Medtronic, its fourth time to receive such recognition. (Boston) (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
EU OKs Biocartis' BRAF mutation test, molecular Dx platform
Biocartis has made its BRAF Mutation Test and Idylla molecular diagnostics platform available commercially in Europe, which comes on the heels of CE mark approval for the products. The BRAF assay, which runs on the Idylla platform, is used to identify the most precise therapy for a form of skin cancer and can generate results in as fast as 90 minutes, the company says. GenomeWeb Daily News (free registration) (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
Science & Health
Researchers developing electronic skin to find lumps in breasts
A study in the journal ACS Applied Materials and Interfaces found that an electronic skin that is capable of "feeling" and imaging small objects shows promise in detecting breast cancer early. The polymer and nanoparticle skin was able to image lumps as deep as 20 millimeters and as small as 5 millimeters in tests using a silicone model. (India)/Indo-Asian News Service (9/11)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Technologies
Beta-O2's artificial pancreas set to undergo clinical trial
Using funding from the Juvenile Diabetes Research Foundation, Beta-O2 is launching a clinical study of its ├čAir device, a bioartificial pancreas that includes insulin- and glucagon-producing Langerhans cells. The trial, which will run for about two years, will test the function, safety and survival of pancreatic endocrine cells implanted in eight patients at a Swedish hospital. (9/11)
Share: LinkedInTwitterFacebookGoogle+Email
Hot Topics
Industry Service Providers
Mitsubishi signs radiotherapy tech supply deal
The SAGA Heavy Ion Medical Accelerator in Japan has tapped Mitsubishi Electric to supply it with pencil-beam scanning radiation therapy technology. The system allows for the precise delivery of individual pencil-beam layer spots without relying on compensators and beam collimation to adjust the areas being targeted, the company said. (free registration) (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
Government & RegulatorySponsored By
FDA clears pedicle screw device from ChoiceSpine
The FDA has given ChoiceSpine 510(k) clearance to market its THUNDERBOLT technology. The minimally invasive pedicle screw system is intended to help surgeons perform small incision procedures. (9/12)
Share: LinkedInTwitterFacebookGoogle+Email
The Value of Medical Technology in Treating Cataracts
Medical technology has substantially improved quality of life for the more than 24.5 million Americans who suffer from cataracts. Download our toolkit to learn how cataract surgery with intraocular lens (IOL) technology can improve quality of life and save costs. Click to Download Toolkit
AdvaMed News
Navigating Japan's New Regulatory Reforms
Monday, Dec. 8, to Tuesday, Dec. 9 -- Washington, D.C.
Thursday, Dec. 11, to Friday, Dec. 12 – San Francisco, Calif.
This intensive, day-and-a-half workshop will help attendees gain knowledge about the revised PMDL law and its impact on medical device companies in Japan; gain high-level knowledge about common market access workflow; and deepen existing knowledge about data and information required in submissions. The scope of the program will cover medical devices and IVD reagents, excluding drugs. Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
Download new tool kit: The Value of Medical Technology to Treat Cataracts
24.5 million Americans suffer from cataracts, a disease that significantly impairs vision and quality of life, and drives up health costs. Tremendous technological progress has been made in cataract surgery and lens technology over the past few decades, improving lives and saving health care dollars. Download and share the tool kit.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Eastern Zone Sales Director Regenesis BiomedicalMultiple Locations, United States
Click here to view more job listings.
Look for a way to lift someone up. If that's all you do, it's enough."
-- Elizabeth Lesser,
American entrepreneur
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Lisa Gough
Advertising:  Meryl Harold
  P: 202.407.7828
Jobs Contact:  Elizabeth Stack

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information